WO2011041737A3 - Gain-of-function bcl-2 inhibitors - Google Patents

Gain-of-function bcl-2 inhibitors Download PDF

Info

Publication number
WO2011041737A3
WO2011041737A3 PCT/US2010/051208 US2010051208W WO2011041737A3 WO 2011041737 A3 WO2011041737 A3 WO 2011041737A3 US 2010051208 W US2010051208 W US 2010051208W WO 2011041737 A3 WO2011041737 A3 WO 2011041737A3
Authority
WO
WIPO (PCT)
Prior art keywords
bcl
inhibitors
gain
function
bci
Prior art date
Application number
PCT/US2010/051208
Other languages
French (fr)
Other versions
WO2011041737A2 (en
Inventor
David Hockenbery
Julian Simon
Original Assignee
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center filed Critical Fred Hutchinson Cancer Research Center
Publication of WO2011041737A2 publication Critical patent/WO2011041737A2/en
Publication of WO2011041737A3 publication Critical patent/WO2011041737A3/en
Priority to US13/437,795 priority Critical patent/US8865901B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C07D213/77—Hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C205/22—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having one nitro groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/295—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/18—Acetic acid esters of trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms

Abstract

Compounds are described that are useful for treating an apoptosis-associated disease, which are specifically cytotoxic to tumor cells that are overexpressing BcI-XL, and are much less cytotoxic in isogenic cells that are not overexpressing BcI-XL. Methods of using such compounds to treat apoptosis-associated disease is also described.
PCT/US2010/051208 2009-10-02 2010-10-01 Gain-of-function bcl-2 inhibitors WO2011041737A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/437,795 US8865901B2 (en) 2009-10-02 2012-04-02 Gain-of-function Bcl-2 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24830409P 2009-10-02 2009-10-02
US61/248,304 2009-10-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051201 Continuation-In-Part WO2011041731A2 (en) 2009-10-02 2010-10-01 Method of inhibiting bcl-2-related survival proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/437,795 Continuation-In-Part US8865901B2 (en) 2009-10-02 2012-04-02 Gain-of-function Bcl-2 inhibitors

Publications (2)

Publication Number Publication Date
WO2011041737A2 WO2011041737A2 (en) 2011-04-07
WO2011041737A3 true WO2011041737A3 (en) 2011-08-18

Family

ID=43446833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/051208 WO2011041737A2 (en) 2009-10-02 2010-10-01 Gain-of-function bcl-2 inhibitors

Country Status (1)

Country Link
WO (1) WO2011041737A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865901B2 (en) 2009-10-02 2014-10-21 Fred Hutchinson Cancer Research Center Gain-of-function Bcl-2 inhibitors
CZ303748B6 (en) * 2011-10-11 2013-04-17 Vysoká skola chemicko - technologická v Praze Phathalazin-1-ylhydrazones and their use in the treatment of tumor diseases
JP2015501792A (en) * 2011-11-10 2015-01-19 メモリアル スローン−ケタリング キャンサー センター Treatment of ovarian cancer with benzylidene benzohydrazide
CZ306554B6 (en) * 2014-05-09 2017-03-08 Vysoká škola chemicko - technologická v Praze Benzoisothiazole-1,1-dioxide-3-hydrazones and their use in anticancer therapy
CN111909082B (en) * 2019-05-07 2022-09-13 湖南大学 Pyridine hydrazone derivatives, and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089745A2 (en) * 2001-05-10 2002-11-14 Cytovia, Inc. Substituted n'-(arylcarbonyl)-benzhydrazides, n'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2006029850A1 (en) * 2004-09-14 2006-03-23 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
WO2010083307A2 (en) * 2009-01-14 2010-07-22 Dow Agrosciences Llc Synergistic fungicidal compositions including hydrazone derivatives and copper

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960704852A (en) 1993-09-30 1996-10-09 오노다 마사요시 Azole derivatives and pharmaceutical compositions thereof
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
EA200000087A1 (en) 1997-07-01 2000-08-28 Атеродженикс, Инк. EFFICIENCY EFFICIENCY IMPROVEMENT OF HYPERPROLIFERATIVE STATE THERAPY WITH THE HELP OF ANTIOXIDANT
US5848379A (en) 1997-07-11 1998-12-08 Exxon Production Research Company Method for characterizing subsurface petrophysical properties using linear shape attributes
US20050239873A1 (en) 1999-08-20 2005-10-27 Fred Hutchinson Cancer Research Center 2 Methoxy antimycin a derivatives and methods of use
JP2001078776A (en) 1999-09-14 2001-03-27 Inst Of Physical & Chemical Res Nade-binding protein
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6632616B2 (en) 2000-03-16 2003-10-14 Duke University Compounds that selectively bind to expanded polyglutamine repeat domains and methods of use thereof
US7241804B1 (en) 2000-08-18 2007-07-10 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing Bcl-2 family member proteins
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
WO2008021211A2 (en) 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
WO2008021250A2 (en) 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089745A2 (en) * 2001-05-10 2002-11-14 Cytovia, Inc. Substituted n'-(arylcarbonyl)-benzhydrazides, n'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2006029850A1 (en) * 2004-09-14 2006-03-23 The Genetics Company, Inc. Hydrazone derivatives and their use as beta secretase inhibitors
WO2010083307A2 (en) * 2009-01-14 2010-07-22 Dow Agrosciences Llc Synergistic fungicidal compositions including hydrazone derivatives and copper

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JOHNSON D K ET AL: "Cytotoxic chelators and chelates 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone", INORGANICA CHIMICA ACTA, ELSEVIER BV, NL, vol. 67, 1 January 1982 (1982-01-01), pages 159 - 165, XP026610789, ISSN: 0020-1693, [retrieved on 19820101], DOI: DOI:10.1016/S0020-1693(00)85058-6 *
MOHAN M ET AL: "SYNTHESIS, CHARACTERIZATION AND ANTITUMOR ACTIVITY OF IRON (II) ANDIRON (III) COMPLEXES OF 3- AND 5-SUBSTITUTED SALICYLALDEHYDE BENZOYL HYDRAZONES", INORGANICA CHIMICA ACTA, ELSEVIER BV, NL, vol. 135, 1 March 1987 (1987-03-01), pages 167 - 177, XP002067536, ISSN: 0020-1693, DOI: DOI:10.1016/S0020-1693(00)81295-5 *
PATIL S A ET AL: "Convenient and efficient Suzuki-Miyaura cross-coupling reactions catalyzed by palladium complexes containing N,N,O-tridentate ligands", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 65, no. 15, 11 April 2009 (2009-04-11), pages 2889 - 2897, XP025970392, ISSN: 0040-4020, [retrieved on 20090211], DOI: DOI:10.1016/J.TET.2009.02.017 *
PRESCOTT B ET AL: "POTENTIAL ANTITUMOR AGENTS: DERIVATIVES OF 2-HYDRAZINO-5-NITROPYRIDINE", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 59, no. 1, 1 January 1970 (1970-01-01), pages 101 - 103, XP009059936, ISSN: 0022-3549, DOI: DOI:10.1002/JPS.2600590120 *
SAREL S ET AL: "DOMAIN-STRUCTURED N1,N2-DERIVATIZED HYDRAZINES AS INHIBITORS OF RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE: REDOX-CYCLING CONSIDERATIONS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 42, no. 2, 1 January 1999 (1999-01-01), pages 242 - 248, XP000910109, ISSN: 0022-2623, DOI: DOI:10.1021/JM980395L *
SARKAR ET AL: "Dioxovanadium(V) complexes with N,N,O-donor monoanionic ligands: Synthesis, structure and properties", POLYHEDRON, PERGAMON PRESS, OXFORD, GB, vol. 26, no. 6, 28 March 2007 (2007-03-28), pages 1205 - 1210, XP022004332, ISSN: 0277-5387, DOI: DOI:10.1016/J.POLY.2006.10.012 *

Also Published As

Publication number Publication date
WO2011041737A2 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
HK1254663A1 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
IL213070A0 (en) Methods for the treatment of infections and tumors
MX2014011134A (en) Carbamate compounds and of making and using same.
GB0700560D0 (en) Device and method for the treatment of diseased tissue such as tumours
WO2013056148A3 (en) Scd1 antagonists for treating cancer
TN2012000555A1 (en) Antibodies to human gdf8
WO2014062720A3 (en) Methods of treating cancer
EA201300171A1 (en) METHODS AND COMPOSITIONS FOR LIVER CANCER THERAPY
HK1162916A1 (en) Methods of treatment for solid tumors
EA201590247A1 (en) ANTIBODIES TO SIGLEC-15
WO2012062925A3 (en) Compounds and methods for treating pain
GB0504988D0 (en) Device and method for the treatment of diseased tissue such as tumors
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2010091049A3 (en) Diagnosis and treatment of cancer
HK1163119A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4
MX2017006167A (en) Glycan-interacting compounds and methods of use.
MX349886B (en) Anti-pseudomonas psl binding molecules and uses thereof.
WO2011047091A9 (en) Methods for treating traumatic brain injury
WO2011066503A3 (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
WO2011041737A3 (en) Gain-of-function bcl-2 inhibitors
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2010101793A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
CA2888908A1 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
WO2011008947A3 (en) Treatment and diagnosis of immune disorders
WO2013106460A3 (en) Compositions and methods for treating malignant astrocytomas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10765545

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10765545

Country of ref document: EP

Kind code of ref document: A2